Detalhe da pesquisa
1.
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin.
Diabetes Obes Metab
; 25(3): 758-766, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36394384
2.
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial.
Sleep Breath
; 27(2): 669-672, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35596030
3.
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.
Diabetes Obes Metab
; 24(9): 1829-1839, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35603908
4.
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
Circulation
; 142(23): 2205-2215, 2020 12 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33026243
5.
Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus.
Diabetes Obes Metab
; 22(4): 574-582, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31797522
6.
Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial.
Eur Heart J
; 39(32): 2959-2971, 2018 08 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29659797
7.
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.
Eur Heart J
; 44(48): 5163-5166, 2023 Dec 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37864578
8.
Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial.
Circulation
; 146(8): 652-654, 2022 08 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-35994565
9.
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.
Diabetes Obes Metab
; 25(5): 1398-1402, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36594154
10.
Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity.
Diabetes Ther
; 14(2): 319-334, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36763328
11.
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.
Circulation
; 117(23): 3002-9, 2008 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-18519851
12.
Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study.
Eur J Cardiovasc Prev Rehabil
; 16(3): 315-20, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19322096
13.
Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia.
Am J Cardiol
; 95(11): 1309-13, 2005 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15904634
14.
Responsiveness of plasma lipids and lipoproteins to plant stanol esters.
Am J Cardiol
; 96(1A): 23D-28D, 2005 Jul 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-15992512
15.
Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
Clin Pharmacol Ther
; 74(3): 236-44, 2003 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-12966367
16.
Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
Am J Cardiol
; 91(8): 956-60, 2003 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12686335
17.
Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial).
Am J Cardiol
; 106(3): 354-9, 2010 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20643245
18.
Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial.
J Am Coll Cardiol
; 54(25): 2353-7, 2009 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20082922
19.
Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
Am J Cardiol
; 103(5): 577-82, 2009 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19231315
20.
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL).
Ann Med
; 40(6): 456-64, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-19160529